Back
4D Molecular Therapeutics, Inc. (FDMT)
BiotechnologyFDMT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$15.86
−1.37%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-2.42
ROE
-34.9%
Gross margin
-145.7%
Debt/Equity
4.54x
Revenue growth
21664.3%
4D Molecular Therapeutics, Inc. — company intelligence
Earnings surprises
Q1 2026$-1.01 vs $-1.01 est+0.2%
Q4 2025$0.43 vs $-0.78 est+155.3%
Q3 2025$-1.01 vs $-1.00 est-1.2%
Q2 2025$-0.98 vs $-0.89 est-9.7%
Analyst consensus · 18 analysts
15 Buy3 Hold0 Sell
Updated Aug 12, 2026
Insider activity · 90 days
7 buys8 sellsnet +154,176 shares
Kirn DavidSell 26,842 · Aug 4, 2026
Kirn DavidSell 12,415 · Aug 3, 2026
Kirn DavidSell 442 · Jul 10, 2026
Recent SEC filings
4 — Insider transaction reportAug 21, 2026
4 — Insider transaction reportAug 17, 2026
10-Q — Quarterly reportAug 13, 2026
Latest news
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why — Yahoo · 1w ago
4DMT Announces New Employment Inducement Grants — Yahoo · 1w ago
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones — Yahoo · 1w ago
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.